OXFORD,
Ohio and COCONUT CREEK,
Fla., April 19, 2022 /CNW/ - PsyBio Therapeutics
Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the
"Company"), an integrated and intellectual property driven
biotechnology company developing novel, bespoke psychoactive
medicinal candidates targeting the potential treatment of mental
health challenges, neurological disorders and other human health
conditions, today announces that Evan
Levine, Chief Executive Officer and Chairman, will present
at the following investor conferences in April 2022:
Benzinga Psychedelics Capital Conference:
Date: April 19 at 11:50 a.m. ET
Registration:
https://www.benzinga.com/events/psychedelics/
Webcast:
https://www.benzinga.com/events/psychedelics/livestream/
Sequire Cannabis & Psychedelic Virtual Conference:
Date: April 20 at 10:30 a.m. ET
Registration & Webcast:
https://cannabis-conference22.mysequire.com/
RHK NobleCon18:
Date: April 20 at 11:30 a.m. ET
Webcast: https://bit.ly/3EoJORD
Registration:
https://www.nobleconference.com/eighteen#register
Mr. Levine will also participate in the 'Mental Wellness:
Psychedelics' panel at NobleCon18, moderated by Eric Bolling:
Date: April 21 at 8:00 a.m. ET
Registration:
https://www.nobleconference.com/eighteen#register
KCSA Virtual Psychedelics Conference:
Date: April 27 at 12:30 p.m. ET
Registration & Webcast: https://bit.ly/37mU2p6
To schedule a meeting with the PsyBio management team, please
contact KCSA Strategic Communications by emailing
PsyBio@kcsa.com.
About PsyBio Therapeutics
Corp.
PsyBio is an integrated and intellectual property driven
biotechnology company developing novel, bespoke psychoactive
medicinal candidates targeting the potential treatment of mental
health challenges, neurological disorders and other human health
conditions. The team has extensive experience in drug discovery
based on synthetic biology and metabolic engineering as well as
clinical and regulatory expertise progressing drugs through human
studies and regulatory protocols. Research and development is
currently ongoing for naturally occurring psychoactive tryptamines
originally discovered in different varieties of hallucinogenic
mushrooms, other tryptamines and phenethylamines and combinations
thereof. The Company utilizes a bio-medicinal chemistry approach to
therapeutic development, in which psychoactive compounds can be
utilized as a template upon which to develop precursors and
analogs, both naturally and non-naturally occurring, specifically
because they are already known to have an effect within the
brain.
PsyBio makes no medical, treatment or health benefit claims
about PsyBio's proposed products. The U.S. Food and Drug
Administration ("FDA") or other similar regulatory authorities have
not evaluated claims regarding psilocybin and other next generation
psychoactive compounds. The efficacy of such products has not been
confirmed by FDA-approved research. There is no assurance that the
use of psilocybin and other psychoactive compounds can diagnose,
treat, cure, or prevent any disease or condition. Vigorous
scientific research and clinical trials are needed. PsyBio has not
conducted clinical trials for the use of its intellectual property.
Any references to quality, consistency, efficacy and safety of
potential products do not imply that PsyBio verified such in
clinical trials or that PsyBio will complete such trials. If PsyBio
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on the PsyBio's
performance and operations.
The TSX Venture Exchange (the "TSXV") has neither approved
nor disapproved the contents of this news release. Neither the TSXV
nor its Regulation Services Provider (as that term is defined in
the policies of the TSXV) accepts responsibility for the adequacy
or accuracy of this release.
SOURCE PsyBio Therapeutics Corp.